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Alzheimer’s disease (AD) and type 2 diabetes
appear to share similar pathogenic mechanisms.
dsRNA-dependent protein kinase (PKR) underlies
peripheral insulin resistance in metabolic disor-
ders. PKR phosphorylates eukaryotic translation
initiation factor 2a (eIF2a-P), and AD brains
exhibit elevated phospho-PKR and eIF2a-P levels.
Whether and how PKR and eIF2a-P participate
in defective brain insulin signaling and cognitive
impairment in AD are unknown. We report that
b-amyloid oligomers, AD-associated toxins, acti-
vate PKR in a tumor necrosis factor a (TNF-a)-
dependent manner, resulting in eIF2a-P, neuronal
insulin receptor substrate (IRS-1) inhibition, syn-
apse loss, and memory impairment. Brain phos-
pho-PKR and eIF2a-P were elevated in AD animal
models, including monkeys given intracerebro-
ventricular oligomer infusions. Oligomers failed
to trigger eIF2a-P and cognitive impairment in
PKR/ and TNFR1/ mice. Bolstering insulin
signaling rescued phospho-PKR and eIF2a-P.
Results reveal pathogenic mechanisms shared by
AD and diabetes and establish that proinflamma-
tory signaling mediates oligomer-induced IRS-1 in-
hibition and PKR-dependent synapse and memory
loss.Cell MINTRODUCTION
Recent evidence suggests that Alzheimer’s disease (AD) is a
novel, brain-specific form of diabetes (de la Monte and Wands,
2008; De Felice, 2013). AD brains exhibit defective insulin
signaling with altered levels and cellular distribution of insulin re-
ceptors (Moloney et al., 2010). Insulin signaling is central to
neuronal survival, regulation of synapse number, and dendritic
plasticity (van der Heide et al., 2005; Chiu et al., 2008; McNay
and Recknagel, 2011), raising the possibility that deficient insulin
signaling may be linked to neuronal dysfunction in AD.
b-amyloid oligomers (AbOs), toxins that accumulate in AD
brains and instigate synapse damage (Ferreira and Klein,
2011), remove insulin receptors from the neuronal surface
(Zhao et al., 2008; De Felice et al., 2009) and activate c-Jun
N-terminal kinase (JNK) to trigger insulin receptor substrate
(IRS-1) inhibition (Bomfim et al., 2012). These findings provided
initial clues on how impaired neuronal insulin signaling de-
velops in AD (De Felice, 2013). Landmark studies from the dia-
betes field have established that activation of proinflammatory
tumor necrosis factor alpha and JNK signaling (TNF-a/JNK
signaling) is a key mechanism leading to peripheral insulin
resistance (Hotamisligil et al., 1994, 1996; Gregor and Hotami-
sligil, 2011). Therefore, it is likely that a molecular parallel exists
between defective brain insulin signaling in AD and peripheral
insulin resistance in diabetes (Bomfim et al., 2012; De Felice,
2013).
The double-stranded RNA-dependent protein kinase (PKR) is
a critical player in the integration of an inflammatory response
that leads to peripheral insulin resistance in metabolic disorders,etabolism 18, 831–843, December 3, 2013 ª2013 Elsevier Inc. 831
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mura et al., 2010). Elevated levels of phosphorylated PKR and of
its key target, eukaryotic translation initiation factor 2a (eIF2a),
have been reported in AD brains and in animal models of AD
(Hoozemans et al., 2009; Yoon et al., 2012). eIF2a phosphoryla-
tion is critical for memory regulation (Costa-Mattioli et al., 2007)
and has been recently shown to mediate prion-related neurode-
generation in the hippocampus (Moreno et al., 2012), a memory
center that is affected early in AD.
Given the pathophysiological roles of TNF-a and PKR in
peripheral insulin resistance (Nakamura et al., 2010; Gregor
and Hotamisligil, 2011), we investigated here whether similar
proinflammatory mechanisms might underlie neuronal dysfunc-
tion in AD. We hypothesized that the TNF-a pathway might
cause phosphorylation of PKR and eIF2a-P, IRS-1 inhibition,
and impact synapses and memory in AD. We show that phos-
pho-PKR and eIF2a-P are elevated in the brains of a transgenic
mouse model of AD, of mice and cynomolgus monkeys given
intracerebroventricular (i.c.v.) infusions of AbOs, and in cultured
hippocampal neurons exposed to oligomers. AbOs failed to
trigger eIF2a-P and cognitive impairment in both PKR/ and
TNFR1/ mice, as well as in mice treated with infliximab, a
TNF-a neutralizing antibody. Salubrinal and thapsigargin, agents
that increase eIF2a-P levels and endoplasmic reticulum (ER)
stress, respectively, inducedmemory impairment inmice. Insulin
treatment prevented oligomer-induced phosphorylation of PKR
and eIF2a-P in hippocampal cultures. Glucagon-like peptide 1
(GLP-1) receptor agonists blocked eIF2a-P in hippocampal cul-
tures and in the brains of transgenic mice and oligomer-injected
monkeys. Collectively, results provide the grounds for targeting
TNF-a/PKR/eIF2a-P signaling as a potential disease-modifying
therapy for AD.
RESULTS
Ab Oligomers Instigate Neuronal eIF2a-P and Other ER
Stress Markers In Vitro and In Vivo
We first explored whether AbOs abnormally activate the
unfolded protein response (UPR), which has been described to
intersect with inflammatory and stress signaling pathways that
lead to peripheral insulin resistance in chronic metabolic dis-
eases (Ozcan et al., 2004, 2006; Hotamisligil, 2010). To this
end, we searched for ER stress markers in cell cultures and in
different animal models of AD. Usingmature cultured hippocam-
pal neurons, we found increased IRE1a-pSer724 in dendrites
and cell bodies after exposure of neurons to AbOs for 3 hr (Fig-
ures 1A and 1B and S1A available online). Consistent with
increased endonuclease activity of IRE1a upon phosphorylation,
levels of spliced X box binding protein 1 (XBP1), a downstream
effector of IRE1a recently proposed as a connection between
UPR and insulin signaling (Park et al., 2010; Winnay et al.,
2010), were increased in oligomer-exposed neurons (Fig-
ure S1B). Further, AbOs increased dendritic and cell body levels
of eIF2a-pSer51 (eIF2a-P) in hippocampal neurons (Figures 1C,
1D, and S1C).
We also detected increased neuronal levels of 78 kDa
glucose-regulated protein (GRP78) (also known as binding
immunoglobulin protein, Bip), an ER chaperone that is part of
the stress response program and is upregulated in AD brains832 Cell Metabolism 18, 831–843, December 3, 2013 ª2013 Elsevier(Hoozemans et al., 2005), in oligomer-exposed neurons (Fig-
ure S1D). Prolonged ER stress is known to trigger apoptosis
mediated by C/EBP homologous protein (CHOP; also known
as growth arrest- and DNA damage-inducible gene 153,
GADD153) (Lai et al., 2007). In line with the results described
above, CHOP mRNA levels were increased in neurons exposed
to AbOs for 24 hr (Figure S1E).
Next, we looked for eIF2a-P in the brains of APPSwe,PS1DE9
(APP/PS1) mice. These mice harbor transgenes for human amy-
loid precursor protein (APP) bearing the Swedish mutation
and a deletion mutant form of presenilin 1 (PS1) and present
increased Ab production and cognitive deficits (Jankowsky
et al., 2001). APP/PS1 mice displayed increased hippocampal
levels of eIF2a-P compared to wild-type animals (Figure 1E).
AbO-Induced PKR Activation Leads to eIF2a
Phosphorylation
Four kinases (PKR-like endoplasmic reticulum kinase [PERK],
double-stranded RNA-dependent protein kinase [PKR], general
control nonrepressed kinase 2 [GCN2], and heme-regulated in-
hibitor [HRI]) have been reported to phosphorylate eIF2a under
stress conditions (Gkogkas et al., 2010). PERK and PKR are
the main eIF2a kinases in response to ER stress and inflamma-
tion, respectively (Raven and Koromilas, 2008). We therefore
examined the roles of both kinases in oligomer-induced eIF2a-P
in neurons. In hippocampal neuronal cultures, the distribution
of activated PERK (PERK-pThr981) was mainly restricted to
cell bodies, and its levels were not altered by exposure to
AbOs for 3 hr (Figures S2A and S2B). In contrast, PKR was acti-
vated by exposure to AbOs in neuronal cultures (Figures 1F and
1G). AbOs are known to selectively target a subset of neurons in
hippocampal cultures (Lacor et al., 2007). Importantly, elevated
phospho-PKR levels were found independent of whether or not
neurons exhibited oligomers bound to their dendrites (Figure 1H).
This indicates that PKR phosphorylation is not triggered by
direct binding of oligomers to individual neurons, but rather is
instigated by soluble factors released to the medium upon
exposure of cultures to AbOs.
To establish the in vivo relevance of these findings, we
analyzed levels of active PKR and PERK in the brains of APP/
PS1 transgenic mice. Increased phosphorylation of PKR, but
not of PERK, was detected in hippocampi of APP/PS1 mice
compared to wild-type controls (Figures 1I and S2C). Consistent
with the role of PKR in AbO-dependent eIF2a-P, pharmacolog-
ical inhibition of PKR completely blocked oligomer-induced
eIF2a-P aswell as IRE1a-pSer724 (Figures 1J and 1K) in cultured
hippocampal neurons. We further extended our investigation
to the brains of monkeys that received i.c.v. infusions of AbOs.
In monkeys, AbOs promoted eIF2a-P (Figures 1L, 1M, S1F,
and S1G) and PKR activation in the hippocampus and entorhinal
cortex (Figures 1N, 1O, S1H, and S1I).
TNF-a Receptor Activation Lies Upstream of PKR
Dysregulation
In metabolic disorders, ER stress has been linked to insulin resis-
tance and proinflammatory TNF-a signaling (Ozcan et al., 2006;
Steinberg et al., 2006). To determine whether TNF-a activation
was involved in AbO-induced phospho-PKR and eIF2a-P in hip-
pocampal neurons, we first treated cultures with infliximab, aInc.
Figure 1. b-Amyloid Oligomers Trigger Neuronal IRE1a-pSer724, eIF2a-P, and Phospho-PKR In Vitro and In Vivo
(A and B) Shown is IRE1a-pSer724 immunolabeling (A) and levels (B) in cultured hippocampal neurons exposed to vehicle or 500 nM AbOs for 3 hr (scale bars =
10 mm). Boxes under each panel show optical zoom images of selected dendrite segments (white dashed rectangles).
(C and D) Shown is eIF2a-P immunolabeling (C) and levels (D), determined from 4–6 experiments using independent cultures (30 images analyzed per experi-
mental condition per experiment).
(E) Immunoblot analysis of eIF2a-P in hippocampal homogenates from 13- to 16-month-old WT (n = 5) or APP/PS1 (n = 7) mice.
(F) Immunolabeling for PKR-pThr451 in cultured hippocampal neurons exposed to vehicle or 500 nM AbOs for 3 hr (scale bar = 10 mm).
(G) PKR-pThr451 immunofluorescence levels, determined from four experiments using independent cultures (30 images analyzed per experimental condition per
experiment).
(H) Immunolabeling of DAPI (blue), AbOs (red), and phospho-PKR (green) in cultured hippocampal neurons. White arrow indicates a neuron with elevated
phospho-PKR level in the absence of oligomer binding.
(I) Immunoblot analysis of PKR-pThr451 (normalized by total PKR) in hippocampal homogenates of 13- to 16-month-old WT (n = 5) and APP/PS1 (n = 7) mice.
*p < 0.05, **p < 0.01, Student’s t test.
(J) eIF2a-P immunolabeling in hippocampal neurons exposed to vehicle, 500 nM AbOs, or 1 mM PKR inhibitor + 500 nM AbOs for 3 hr (scale bar = 10 mm).
(K) eIF2a-P and IRE1a-pSer724 immunofluorescence levels, determined from three experiments using independent cultures. *p < 0.05, ANOVA followed by
Bonferroni post hoc test.
(L and M) Shown is eIF2a-P immunolabeling (L) and integrated optical densities (M) in hippocampus (CA1 and CA3 regions) and entorhinal cortex of cynomolgus
monkeys that received i.c.v. injections of AbOs (n = 4) (right panels) compared to sham-operated control monkeys (n = 3) (left panels) (scale bars = 200 mm).
(N and O) Shown is phosphor-PKR labeling (N) and integrated optical densities (O) (see Experimental Procedures) in hippocampus (CA1 and CA3 regions) and
entorhinal cortex of sham-operated (Sham) (n = 3) or AbO-injected monkeys (AbOs) (n = 4). *p < 0.05, ANOVA followed by Bonferroni post hoc test. Graphs show
means ± SEM. See also Figure S1.
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Figure 2. TNF-a Mediates Oligomer-
Induced Phospho-PKR and eIF2a-P
(A) PKR-pThr451 immunolabeling in cultured hip-
pocampal neurons exposed for 3 hr to vehicle or
500 nM AbOs in the absence or presence of in-
fliximab.
(B) PKR-pThr451 immunofluorescence levels,
determined from four experiments using inde-
pendent cultures.
(C) eIF2a-P immunolabeling in cultured hippo-
campal neurons exposed for 3 hr to vehicle or
500 nM AbOs in the absence or presence of in-
fliximab.
(D) eIF2a-P immunofluorescence levels, deter-
mined from four experiments using independent
cultures exposed to vehicle or 500 nM AbOs in the
absence or presence of infliximab or JNK inhibitor
(JNKi). **p < 0.01, ANOVA followed by Bonferroni
post hoc test.
(E) Immunoblot analysis for eIF2a-P in hippo-
campal neuronal cultures exposed for 3 hr to
500 nM AbOs in the absence or in the presence of
infliximab or JNK inhibitor (n = 3 independent ex-
periments; *p < 0.05, Student’s t test).
(F) Imunolabeling of AbOs (with anti-AbO, NU4) in
neurons exposed to 500 nM AbOs in the absence
or presence of infliximab.
(G) Quantification of Ab oligomer binding in neu-
rons exposed to AbOs in the absence or presence
of infliximab.
(H) Soluble TNF-a levels in conditionedmedia from
cultured hippocampal neurons exposed to vehicle
(veh) or 500 nM AbOs for 3 hr (n = 3 independent
experiments; *p < 0.05, Student’s t test). Graphs
show means ± SEM. See also Figure S2.
Cell Metabolism
TNF-a, PKR, Insulin Signaling, and MemoryTNF-a neutralizing monoclonal antibody. Infliximab suppressed
both PKR activation and eIF2a-P triggered by oligomers (Figures
2A–2E). SP600125, a specific JNK inhibitor, also blocked eI-
F2a-P in neuronal cultures (Figures 2D and 2E), in line with recent
studies that have implicated the JNK pathway in AbO-induced
IRS-1 inhibition (Ma et al., 2009; Bomfim et al., 2012; De Felice,
2013). It is notable that infliximab did not block oligomer binding
to neurons (Figures 2F and 2G), substantiating the notion that
activation of TNF-a/PKR signaling is independent of direct bind-
ing of AbOs to individual neurons and is likely mediated by TNF-a
secreted to the medium. Indeed, TNF-a levels were increased in
the culture medium after exposure to oligomers (Figure 2H),
consistent with our recent finding that TNF-a levels are increased
in the brains of mice that received i.c.v infusions of oligomers
(Ledo et al., 2013).
Activation of the TNF-a/PKR/eIF2a-P Pathway Is Linked
to Synapse Loss and Memory Impairment
We next hypothesized that activation of proinflammatory TNF-a
signaling might be connected to AbO-induced memory impair-
ment. Supporting this hypothesis, infliximab prevented memory
impairment triggered by AbOs in mice (Figure 3A). We next
injected oligomers i.c.v. in TNFR1/ mice. Significantly, AbOs
caused memory deficits in wild-type (WT) mice, but not in
TNFR1/mice (Figures 3B, 3C, and S3). These results implicate
TNF-a signaling in the mechanism underlying memory impair-
ment induced by AbOs in mice. Interestingly, AbOs triggered834 Cell Metabolism 18, 831–843, December 3, 2013 ª2013 Elsevierphosphorylation of PKR and eIF2a in the hippocampus of WT
mice, but not in TNFR1/mice (Figures 3D and 3E), establishing
that activation of TNF-a receptors lies upstream of PKR and
eIF2a-P in vivo.
Synapse loss has been proposed to be the best pathological
correlate of the extent of dementia in AD (Terry et al., 1991), and
AD brains present reduced levels of synaptophysin and PSD-
95, pre- and postsynaptic markers, respectively (Terry et al.,
1991).AbOshavebeenshown to reduce the levelsof synaptophy-
sin or PSD-95 in neuronal cultures, in the brains of mice receiving
i.c.v. infusions of oligomers, and in ex vivo human cortical slices
(Sebollela et al., 2012; Figueiredo et al., 2013). Supporting the
notion that synaptic deterioration underlies TNF-a-dependent
memory impairment induced by AbOs, levels of synaptophysin
and PSD-95 were decreased in hippocampi of WT, but not of
TNFR1/, mice i.c.v. injected with AbOs (Figure 3F).
To determine the role of PKR in AbO-induced cognitive impair-
ment, we investigated the effect of AbOs in PKR/mice. Impor-
tantly, we found that AbOs induced hippocampal eIF2a-P and
cognitive deficits in WT mice, but not in PKR/ mice (Figures
3G–3I). These results demonstrate that PKR, recently implicated
in metabolic stress and impaired insulin signaling in diabetes
(Nakamura et al., 2010), is a key mediator of neuronal eIF2a-P
and memory impairment induced by AbOs.
To further examine the impact of PKR activation on synapses,
we exposed hippocampal cultures to AbOs in the absence or
presence of a PKR inhibitor. After 24 hr, we evaluated synapseInc.
Figure 3. TNF-a/PKR Signaling Mediates
Cognitive Impairment and Synapse Loss
Caused by Ab Oligomers
(A) Exploration times of mice i.c.v. injected with
vehicle or 10 pmol AbOs in the absence or pres-
ence of infliximab in the novel object recognition
task (n = 7–10 per experimental group).
(B) Exploration times of WT or TNFR1/ mice
i.c.v. injected with vehicle or 10 pmol AbOs in
the novel object recognition task (n = 9–10 per
experimental group). Asterisks denote a statisti-
cally significant (p < 0.05) difference from 50%
(reference value).
(C) Freezing times of WT or TNFR1/ mice in-
jected with vehicle or 10 pmol AbOs in the
contextual fear conditioning task. n = 9–10 animals
per experimental group. *p < 0.05, ANOVA fol-
lowed by Bonferroni post hoc test.
(D–F) Immunoblot analysis of PKR-pThr451
(normalized by total PKR) (D), eIF2a-P (normalized
by total eIF2a) (E), and synaptophysin (white bars)
and PSD95 (gray bars) (normalized by b-actin) (F)
in hippocampal homogenates of 2- to 3-month-old
WT or TNFR1/ mice injected with vehicle or 10
pmol AbOs (n = 7 for each experimental condition).
(G) Exploration times of WT or PKR/ mice
exposed to vehicle or 10 pmol AbOs in the novel
object recognition task (n = 8–10 per experimental
group). Asterisks denote a statistically significant
difference (p < 0.05) from 50% (reference value).
(H) Freezing times of WT or PKR/ mice injected
with vehicle or 10 pmol AbOs in the contextual fear
conditioning task. n = 9–10 animals per experi-
mental group. *p < 0.05, ANOVA followed by
Bonferroni post hoc test.
(I) Immunoblot analysis of eIF2a-P (normalized
by total eIF2a) in hippocampal homogenates of 2-
to 3-month-old WT or PKR/ mice injected with
vehicle or 10 pmol AbOs (n = 7 for each experi-
mental condition).
(J) Synaptophysin (green) and PSD95 (red) im-
munolabeling of cultured hippocampal neurons
exposed for 3 hr to vehicle or 500 nM AbOs in
the absence or presence of PKR inhibitor. Syn-
apses, evidenced by colocalized puncta, appear
in yellow.
(K–M) Quantification of synaptophysin (K), PSD95
(L), and colocalized (M) puncta, determined from
four experiments using independent cultures. *p <
0.05, ANOVA followed by Bonferroni post hoc test.
Graphs show means ± SEM. See also Figure S3.
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PSD-95 and their colocalization at synapses. Results showed
that inhibition of PKR attenuated synapse loss induced by
AbOs (Figures 3J–3M) and suggest that loss of synaptic proteins
underlies the deleterious effects of PKR on memory.
Based on the findings described above, we hypothesized that
elevated eIF2a-P in the brain might be linked to memory impair-
ment triggered by AbOs. To explore the connection between
eIF2a-P and memory, we performed i.p. injections of salubrinal
(an inhibitor of GADD34, a phosphatase that preferentially
dephosphorylates eIF2a) to increase eIF2a-P levels in the hippo-
campi of adult Swiss mice. Animals that received salubrinal
presented memory impairment in the novel object recognition
task (Figure 4A) and significantly lower hippocampal levels ofCell MPSD-95 and synaptophysin (Figures 4B–4D). We also found
decreased levels of synaptophysin and PSD-95, as well as
decreased synapse density, in salubrinal-exposed hippocampal
cultures (Figures 4E–4H). Control experiments indicated that, as
expected, salubrinal promoted eIF2a-P in hippocampal neurons
in culture (Figures S4A and S4B) and in the brains of injected
mice (Figure S4C). These results show that eIF2a-P is sufficient
to cause memory impairment and synapse loss in mice.
Additional support to the notion that eIF2a-P and, more gener-
ally, ER stress cause memory impairment came from the obser-
vation that thapsigargin, a classical inducer of ER stress that
triggers eIF2a-P in neurons (Figures S5A and S5B), caused brain
eIF2a-P and memory impairment when injected i.c.v. in mice
(Figures S5C and S5D). 4-phenylbutyrate (4-PBA), a chemicaletabolism 18, 831–843, December 3, 2013 ª2013 Elsevier Inc. 835
Figure 4. eIF2a-P Triggers Cognitive
Impairment and Synapse Loss
(A) Exploration times ofmice i.p. injected for 7 days
with vehicle or 1 mg/kg salubrinal in the novel
object recognition task (n = 10 per experimental
group). Asterisks denote a statistically significant
difference (p < 0.05) from 50% (reference value).
(B) Representative immunoblot analysis of syn-
aptophysin and PSD-95 levels in hippocampal
homogenates of 2- to 3-month-old mice receiving
vehicle or salubrinal intraperitoneally for 7 days
(n = 7 per experimental group).
(C and D) Levels of synaptophysin (C) and PSD-95
(D) were normalized by b-actin.
(E) Synaptophysin (green) and PSD95 (red) im-
munolabeling in cultured hippocampal neurons
exposed for 3 hr to vehicle or 10 mM salubrinal.
Synapses, evidenced by colocalized puncta,
appear in yellow.
(F–H) Quantification of synaptophysin (F), PSD-95
(G), and colocalized (H) puncta, determined from
four experiments using independent cultures.
*p < 0.05, Student’s t test. Graphs show means ±
SEM. See also Figure S4.
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(Figure S5D). 4-PBA further blockedmemory impairment caused
by i.c.v. injection of AbOs in mice (Figure S5E), implicating ER
stress in the impact of AbOs on memory.
TNF-a, but Not eIF2a-P, Causes Neuronal IRS-1
Inhibition
We recently reported that TNF-a and PKR mediate IRS-1 inhibi-
tion in cultured hippocampal neurons (Bomfim et al., 2012).
Establishing that proinflammatory TNF-a mediates oligomer-
induced IRS-1 inhibition in vivo, AbOs triggered IRS-1pSer636
in the hippocampus of WT mice, but not in TNFR1/ mice
(Figure 5A). We also examined IRS-1pSer levels in the brains of
PKR/ mice. Possibly reflecting different patterns of activation
of IRS-1 in mice of different genetic backgrounds (Xu et al.,
2013), we did not detect increased IRS-1pSer levels induced
by AbOs in WT 129/SvEv mice. Interestingly, however, lower
IRS-1pSer levels were found in PKR/ mice than in WT mice,
demonstrating that suppression of PKR per se attenuates
IRS-1 inhibition (Figure 5B).
Because ER stress and eIF2a-P are linked to insulin resistance
in peripheral tissues (Ozcan et al., 2004; Birkenfeld et al., 2011),
we next aimed to determine whether they might be related to
IRS-1 inhibition in neurons. We initially found that thapsgargin
triggered dendritic IRS-1pSer636 in hippocampal neurons, and
this was blocked by 4-PBA (Figures 5C and 5D). However, levels
of IRS-1pSer were unaffected in hippocampal neuronal cultures
exposed to salubrinal (Figures 5E and 5F) or in hippocampi of
salubrinal-injected mice (Figures 5G and 5H). These results sug-
gest that, while eIF2a-P alone is not sufficient to cause IRS-
1pSer in neurons, aberrant activation of TNF-a signaling and
induction of ER stress play important roles in brain IRS-1 inhibi-
tion. In this regard, it is interesting to note that AbOs induced
upregulation of XBP1s, GRP78, and CHOP (Figures S1B, S1D,
and S1E), implicated in mechanisms by which ER dysfunction
is linked to inflammatory signaling and insulin resistance
(Hotamisligil, 2010). Based on our results, it is conceivable that836 Cell Metabolism 18, 831–843, December 3, 2013 ª2013 Elsevierdifferent branches of the UPR respond to AbO-induced TNFR
activation and lead to IRS-1 inhibition.
Stimulation of Insulin Signaling Prevents Phospho-PKR
and eIF2a-P
Lastly, we asked whether antidiabetic agents, recently shown to
restore insulin signaling and exert neuroprotective actions in AD
models (De Felice et al., 2009; McClean et al., 2011; Bomfim
et al., 2012), could alleviate phospho-PKR and eIF2a-P triggered
by AbOs. Insulin treatment blocked the phosphorylation of PKR
and eIF2a in hippocampal cultures exposed to AbOs (Figures
6A–6D). Exendin-4, a GLP-1 receptor agonist approved for
treatment of diabetes (Ryan and Hardy, 2011), blocked AbO-trig-
gered eIF2a-P in hippocampal neurons (Figures 6C and 6D), and
intraperitoneal treatment with exendin-4 rescued eIF2a-P levels
in hippocampi of APP/PS1 mice (Figure 6E).
Liraglutide, a long-lasting GLP-1 receptor agonist, has also
been shown to exhibit neuroprotective actions in animal models.
Liraglutide treatment significantly reduced the levels of ER stress
marker GRP78 in the brains of APP/PS1 mice (Figure S6A). This
was accompanied by a significant increase in levels of synaptic
marker drebrin (Figure S6B), suggesting increased synaptic
density. We further asked whether liraglutide would affect hippo-
campal Ab oligomer burden in APP/PS1 mice. Interestingly,
levels of 28 kDa and 108 kDa Ab oligomers, recently implicated
in AD pathogenesis (Tomiyama et al., 2010; Bao et al., 2012),
were markedly reduced in liraglutide-treated animals (Figures
S6C and S6D).
The neuroprotective actions of exendin-4 and liraglutide trans-
lated into memory benefit, as indicated by improved perfor-
mance in fear conditioning learning in APP/PS1 mice (Figures
S6E and S6F). These findings are in line with recent studies
that demonstrated beneficial effects of GLP-1R activation
on memory in AD mice (McClean et al., 2011; Bomfim et al.,
2012). Control measurements showed that neither exendin-4
nor liraglutide altered animal body weight during experiments
(Figures S6G and S6H). Collectively, these data suggest thatInc.
Figure 5. TNF-a and ER Stress, But Not
eIF2a-P Alone, Cause Neuronal IRS-1
Inhibition
(A) Immunoblot analysis of IRS-1pSer636
(normalized by total IRS-1) in hippocampal ho-
mogenates of 2- to 3-month-old WT or TNFR1/
mice injected with vehicle or 10 pmol AbOs (n = 7
for each experimental condition).
(B) Immunoblot analysis of IRS-1pSer636 in hip-
pocampal homogenates of 2- to 3-month-old WT
or PKR/ mice injected with vehicle or 10 pmol
AbOs (n = 8 for each experimental condition).
(C) MAP2 and IRS-1pSer636 immunolabeling
in dendrite segments from hippocampal neurons
exposed to vehicle, 1 mM thapsigargin, or 1 mM
4-PBA + 1 mM thapsigargin for 3 hr.
(D) Graph shows IRS-1pSer636 immunofluo-
rescence levels (3 independent experiments; 80
dendrite segments analyzed per experimental
condition per experiment). Scale bar: 5 mm.
(E) IRS-1pSer636 immunolabeling in cultured
hippocampal neurons exposed to vehicle or 10 mM
salubrinal for 3 hr (scale bars = 10 mm).
(F) Graph shows IRS-1pSer636 immunofluo-
rescence levels (3 independent experiments; 30
images/experimental condition/experiment).
(G) Representative immunoblot analysis of IRS-
1pSer636 (normalized by total IRS-1) in hippo-
campal homogenates of 2- to 3-month-old mice
injected intraperitoneally with vehicle or 1 mg/kg
salubrinal (n = 7 per experimental condition).
(H) IRS-1pSer636 levels were normalized by total
IRS-1. *p < 0.05, ANOVA followed by Bonferroni
post hoc test. Graphs show means ± SEM. See
also Figure S5.
Cell Metabolism
TNF-a, PKR, Insulin Signaling, and Memorythe beneficial actions of GLP-1R agonists in AD transgenic
mice involve decreased AbO levels and attenuation of brain
eIF2a-P and ER stress. Finally, systemic treatment with liraglu-
tide reduced eIF2a-P induced by AbOs in the entorhinal cortex
and hippocampus of two cynomolgus monkeys (Figures 6F–6H).
DISCUSSION
An intriguingmolecular connectionhasbeenestablishedbetween
type 2 diabetes and AD, following the discovery that impaired
insulin signaling, a hallmark of diabetes, is present in AD brains
(Bomfimetal., 2012;Talbotet al., 2012).Clinical andepidemiolog-
ical studies have further linked AD and diabetes, with each dis-
ease increasing the risk of developing the other (Ott et al., 1996;
Janson et al., 2004). AbOs, synaptotoxins that accumulate in AD
brains (Gong et al., 2003), were recently found to disrupt neuronal
insulin signaling by causing cellular redistribution of insulin recep-
tors and inhibitory serine phosphorylation of IRS-1 (Zhao et al.,
2008; De Felice et al., 2009; Bomfim et al., 2012). These studiesCell Metabolism 18, 831–843,have provided initial evidence that
mechanisms similar to those underlying
peripheral insulin resistance in metabolic
diseases lead to impaired brain insulin
signaling in AD (Bomfim et al., 2012;
Talbot et al., 2012; De Felice, 2013).AbOs exert multiple neurotoxic actions, including disruption
of neuronal calcium homeostasis (De Felice et al., 2007;
Mattson, 2010), abnormal ER calcium release (Paula-Lima
et al., 2011), and activation of JNK (De Felice et al., 2009;
De Felice, 2013), conditions known to favor the development
of ER stress in peripheral tissues (Hotamisligil, 2010). ER stress
plays a key role in metabolic disorders, including type 2 dia-
betes and obesity, and is linked to peripheral insulin resistance
and inflammation (Ozcan et al., 2004). Elevated ER stress
markers, including eIF2a-P, have been reported in AD brains
(Hoozemans et al., 2009; Yoon et al., 2012). Using different
experimental models, including monkeys that received i.c.v.
injections of AbOs, we demonstrate here that eIF2a-P and
other ER stress responses are induced by AbOs in neurons.
Our findings are in accord with studies that reported elevated
levels of ER stress markers in other cellular and animal
models of AD (Yoon et al., 2012) and indicate that pathological
findings in those studies can be attributed to the toxic impact
of AbOs.December 3, 2013 ª2013 Elsevier Inc. 837
Figure 6. Antidiabetic Agents Block AbO-Induced eIF2a-P In Vitro and In Vivo
(A) PKR-pThr451 immunolabeling in cultured hippocampal neurons exposed for 3 hr to vehicle or 500 nM AbOs in the absence or presence of 1 mM insulin (scale
bar = 10 mm).
(B) PKR-pThr451 immunofluorescence levels, determined from four experiments using independent cultures.
(C) eIF2a-P immunolabeling in hippocampal neurons exposed for 3 hr to 500 nM AbOs, 1 mM insulin + 500 nM AbOs, or 300 nM exendin-4 + 500 nM AbOs (scale
bar = 10 mm).
(D) eIF2a-P immunofluorescence levels (n = 3 experiments using independent cultures; 30 images analyzed per experimental condition per experiment).
**p < 0.01, ANOVA followed by Bonferroni post hoc test.
(E) Immunoblot analysis for eIF2a-P in hippocampal homogenates from 13- to 16-month-old APP/PS1 (n = 7) or exendin-4-treated APP/PS1 (n = 5) mice. Graphs
show means ± SEM.
(F) eIF2a-P immunolabeling in the hippocampi (representative images from CA3) and entorhinal cortices of sham, AbO-injected, or liraglutide-treated and
AbO-injected monkeys (scale bars = 200 mm).
(G and H) eIF2a-P immunolabeling densities in the hippocampi (G) and entorhinal cortices (H) of sham (white bar), AbO-injected (black bar), or liraglutide-treated
AbO-injectedmonkeys (gray bars). Graphs showmeans ± SEM obtained for different animals in each experimental group (n = 3, 4, or 2 for sham, AbO-injected, or
liraglutide-treated AbO-injected monkeys, respectively). Asterisk indicates a statistically significant (p < 0.05; Student’s t test) difference between sham and
AbO-injected animals. See also Figure S6.
Cell Metabolism
TNF-a, PKR, Insulin Signaling, and MemoryWe have identified PKR as an eIF2a kinase activated by AbOs
in neurons and shown that AbOs act via the TNF-a pathway to
activate PKR. Active PKR, present in AD brains (Bullido et al.,
2008), is an important mediator of inflammation and IRS-1
dysfunction in metabolic diseases (Nakamura et al., 2010; Gre-
gor and Hotamisligil, 2011). Of direct relevance to the current
study, PKR was recently shown to be involved in neuronal IRS-
1 inhibition triggered by AbOs (Bomfim et al., 2012) and to nega-838 Cell Metabolism 18, 831–843, December 3, 2013 ª2013 Elseviertively regulate memory in mice (Zhu et al., 2011). Current findings
indicate that PKR activation does not depend on direct binding
of oligomers to individual neurons, as elevated phospho-PKR
and eIF2a-P levels were detected in neurons regardless of
whether or not they had oligomers bound to their dendrites.
Therefore, AbOs do not seem to act directly on neurons to phos-
phorylate PKR. Rather, it is likely that a crosstalk between neu-
rons and microglia leads to elevated levels of TNF-a, causingInc.
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TNF-a, PKR, Insulin Signaling, and Memoryactivation of neuronal TNF-a/PKR/eIF2a signaling. TNF-a has
been suggested recently to play a role in brain dysfunction in
different diseases, including AD, trauma, and Parkinson’s dis-
ease (Clark et al., 2012). Elevated TNF-a levels are further
thought to cause cognitive deficits (He et al., 2007). Our results
demonstrate that, in Alzheimer’s disease, elevated TNF-a is a
consequence of the brain accumulation and impact of AbOs.
AD is a devastating disease affecting memory. AbOs are
recognized as potent synaptotoxins that inhibit synaptic plas-
ticity (Ferreira and Klein, 2011). We found here that oligomer-
induced aberrant TNF-a/PKR/eIF2a signaling and induction of
ER stress are linked to synapse loss and memory impairment.
It is notable that, in both PKR/ and TNFR1/mice, oligomers
failed to trigger eIF2a-P and cognitive impairment. Inhibition of
PKRwas found to attenuate the loss of PSD-95 and synaptophy-
sin induced by AbOs, implicating synapse deterioration in the
deleterious impact of PKR on memory. PKR and eIF2a have
both been shown to be critical for memory regulation (Costa-
Mattioli et al., 2007; Zhu et al., 2011). More recently, eIF2a-P
was found to mediate prion-related neurodegeneration in the
hippocampus (Moreno et al., 2012). We report that upregulation
of eIF2a-P triggers synapse loss, suggesting that synergistic
neurotoxic events that culminate in eIF2a-P may respond, at
least in part, for synapse damage in AD. Our results thus estab-
lish that AbO-induced TNFa, PKR, and eIF2a-P dysregulation is
directly linked to synapse failure and cognitive impairment,
revealing a mechanism by which AbOs disrupt memory in AD.
The parallel we now describe between AD and diabetes sheds
light on how insulin signaling is impaired in AD. In peripheral tis-
sues, inflammatory and metabolic stress signaling cascades
trigger disruption of insulin signaling (Ozcan et al., 2004, 2006;
Hotamisligil, 2010; Nakamura et al., 2010; Gregor and Hotamisli-
gil, 2011). Our findings show that ER stress is linked to neuronal
IRS-1 inhibition andmay act synergistically with proinflammatory
signals to disrupt brain insulin signaling in AD.
It is important to note that our conclusion that TNF-a signaling
is linked to both defective brain insulin signaling and memory
impairment caused by AbOs does not necessarily imply that
memory impairment is a direct consequence of disruption of
insulin signaling. In fact, the role of insulin signaling in memory
formation, and how defective signaling might result in neurode-
generative disorders, is still under investigation. While insulin
has been shown to positively modulate hippocampal synaptic
plasticity (van der Heide et al., 2005), an early study showed
that spatial memory was preserved in neural-specific insulin re-
ceptor b subunit knockout (NIRKO) mice (Schubert et al., 2004).
A recent study, however, reported that IRb haploinsufficiency
causes reduced brain insulin signaling and defects in late-phase
long-term potentiation (LTP) and long-term recognition memory
storage, thereby implicating insulin receptor (IR)-dependent
mechanisms in memory formation (Nistico` et al., 2012). Signifi-
cantly, intranasal insulin administration has been found to
enhance memory in healthy volunteers (Benedict et al., 2004),
in memory-impaired older subjects (Reger et al., 2006), and
in early AD patients (Craft et al., 2012), with beneficial effects
reported for both acute and long-term insulin treatment.
In sporadic AD (which corresponds to >90% of AD cases), the
exact mechanism that leads to accumulation of Ab oligomers
and amyloid in the brain remains to be fully elucidated. Interest-Cell Mingly, eIF2a-P promotes BACE1 expression, Ab production, and
deposition (O’Connor et al., 2008). Thus, AbO-induced TNF-a,
PKR, and eIF2a-P may constitute a hub in a feedforward delete-
rious cycle involving increased AbO generation and perpetuation
and amplification of neuronal dysfunction.
In line with our current findings demonstrating that eIF2a-P is
sufficient to cause synapse loss and memory impairment in
mice, a very recent study showed that the eIF2a kinase PERK
mediates Ab-induced LTP impairment (Ma et al., 2013). Impor-
tantly, Ma and colleagues further reported that genetically sup-
pressing the eIF2a kinases PERK or GCN2 prevented spatial
memory impairment in AD mice (Ma et al., 2013). Although
the complete set of mechanisms remains to be elucidated,
it is conceivable that TNF-a represents an initial trigger that
orchestrates activation of multiple stress response pathways
(of which the PKR/eIF2a pathway here investigated appears
central) that culminate with synapse dysfunction and memory
loss in AD.
In recent years, there has been a strong effort to develop new
therapeutic strategies for diabetes and insulin resistance disor-
ders. GLP-1 receptor stimulation has insulinotropic action and
restores glucose homeostasis in peripheral tissue (Yusta et al.,
2006), and several GLP-1 analogs are currently used for diabetes
treatment. We demonstrate here that both insulin and GLP-1R
agonists prevent abnormal neuronal phospho-PKR and eIF2a-P.
The observation that insulin protects neurons from AbO-induced
PKR activation suggests that blockade of eIF2a-P by insulin is
mediated by suppression of PKR. Recent studies have shown
beneficial effects of exendin-4 and liraglutide against neurode-
generation and cognitive impairment in AD models (Li et al.,
2010; McClean et al., 2011; Bomfim et al., 2012), but the
signaling mechanisms involved in neuroprotection are only
partially known. The present study suggests a mechanism
involving suppression of the PKR/eIF2a-P pathway. Importantly,
we provide evidence that a GLP-1R agonist exerts neuroprotec-
tive actions in the primate brain, as systemic liraglutide treatment
reduced oligomer-induced brain eIF2a-P in monkeys.
In conclusion, our findings establish that activation of TNF-a
signaling mediates AbO-induced brain IRS-1 inhibition and
PKR-dependent eIF2a-P, synapse loss, and memory impair-
ment (Figure 7), revealing mechanisms that lead to synapse
loss and memory impairment. Identifying a pathogenic mecha-
nism that is shared between AD and diabetes and contributes
to memory loss in AD may open avenues for rapid implemen-
tation of clinically approved antidiabetic drugs as therapeutics
in AD.EXPERIMENTAL PROCEDURES
Ab Oligomers
Oligomers were prepared weekly from synthetic Ab1–42 and routinely charac-
terized by size-exclusion chromatography and, occasionally, by western
immunoblots and transmission electron microscopy, as previously described
(De Felice et al., 2007, 2008; Sebollela et al., 2012). Oligomers were kept at
4C and used within 48 hr of preparation.
Mature Hippocampal Cultures
Primary rat hippocampal neuronal cultures, prepared and developed in
Neurobasal Medium supplemented with B27 (Invitrogen) and antibiotics
according to established procedures (De Felice et al., 2007), were used afteretabolism 18, 831–843, December 3, 2013 ª2013 Elsevier Inc. 839
Figure 7. Ab Oligomers Trigger Synapse Loss, Memory Impairment,
and IRS-1 Inhibition via TNF-a/PKR Signaling
Ab oligomers lead to increased brain levels of TNF-a, leading to TNFR1-
mediated activation of PKR and other stress kinases. Activated PKR phos-
phorylates neuronal IRS-1 (see also Bomfim et al., 2012) and eIF2a. Increased
eIF2a-P levels trigger synapse loss and memory impairment.
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TNF-a, PKR, Insulin Signaling, and Memory18–21 days in vitro. All procedures were approved by the Institutional Animal
Care and Use Committee of the Federal University of Rio de Janeiro (protocol
#IBqM 022). Cultures were exposed at 37C for 3 hr to 500 nM Ab oligomers
or an equivalent volume of vehicle (2% DMSO in phosphate-buffered
saline [PBS]). When present, PKR inhibitor (1 mM), insulin (1 mM), exendin-4
(300 nM), SP600125 (10 mM), or infliximab (1 mg/mL) were added to cultures
30 min before Ab oligomers. For ER stress induction, thapsigargin (1 mM)
was added to neuronal cultures for 3 hr, and in some experiments 4-phenylbu-
tyrate (4-PBA) (1 mM) was also present. For eIF2a-P induction, salubrinal
(10 mM) was added to neuronal cultures for 3 hr.
Experimental Subjects
Male Swiss mice were obtained from our animal facility (Federal University of
Rio de Janeiro) and were 2.5–3 months old at the beginning of experiments.
PKR/ male mice on a 129/SvEv background (Yang et al., 1995) were
obtained from Federal University of Minas Gerais Animal Centre. 129/SvEv
wild-type mice were used as controls for experiments with PKR/ mice.
TNFR1/ (TNFRp55/) female mice on a C57BL/6 background (Pfeffer
et al., 1993) were obtained from the University of Campinas Breeding Centre840 Cell Metabolism 18, 831–843, December 3, 2013 ª2013 Elsevierand were 3 months old at the beginning of experiments. C57BL/6 wild-type
mice were used as controls for experiments with TNFR1/ mice. APPSwe/
PS1DE9 mice on a C57BL/6 background (Jankowsky et al., 2001) were ob-
tained from The Jackson Laboratory. Wild-type littermates were used as con-
trols. Animals were genotyped prior to the studies using specific primers (see
Supplemental Experimental Procedures). All procedures involving transgenic
mice were approved by the Institutional Animal Care and Use Committee of
the Federal University of Rio de Janeiro (protocol #IBqM 055). Animals were
housed in groups of five in each cage with free access to food and water,
with controlled room temperature and humidity, and under a 12 hr light/12 hr
dark cycle. All procedures used in the present study followed the ‘‘Principles
of Laboratory Animal Care’’ from the US National Institutes of Health.
Intracerebroventricular Injections in Mice
For i.c.v. injection of AbOs, animals were anesthetized for 7 min with 2.5% iso-
flurane (Crista´lia) using a vaporizer system and gently restrained only during
the injection procedure itself, as described (Figueiredo et al., 2013; Ledo
et al., 2013). A 2.5 mm long needle was unilaterally inserted 1 mm to the right
of the midline point equidistant from each eye and 1 mm posterior to a line
drawn through the anterior base of the eye (Ledo et al., 2013). AbOs
(10 pmol), 1 mg of thapsigargin, or vehicle was injected in a final volume of
3 ml, and the needle was kept in place for 30 s to avoid backflow. Before eutha-
nasia, blue staining was injected using the same hole used previously, which
allowed us to determine the accurate placement of the injection. Behavioral
results from mice that showed signs of misplaced injections or any sign of
hemorrhage were excluded from the final statistical analysis (this happened
in 5% of cases, on average).
In Vivo Drug Treatments in Mice
Exendin-4 and liraglutide are two long-lasting GLP-1 receptor agonists.
APPSwe/PS1DE9 mice (13–14 months old) received daily intraperitoneal
injections of exendin-4 (25 nmol/kg, dissolved in saline) or vehicle (saline) for
3 weeks. Another group of transgenic animals received daily intraperitoneal
injections of liraglutide (25 nmol/kg, dissolved in saline) or vehicle (saline) for
6 weeks. Male Swiss mice (3 months old) received daily intraperitoneal
injections of infliximab (20 mg/day) for 7 days starting immediately after i.c.v.
injection of AbOs. In experiments with 4-phenylbutyrate (4-PBA), one intraper-
itoneal injection (200mg/kg) was given immediately after i.c.v injection of either
Ab oligomers or thapsigargin in male Swiss mice. 4-PBA solutions were pre-
pared as described. Salubrinal (1 mg/kg) or vehicle was administered intraper-
itoneally in 3-month-old male Swiss mice for 7 days before cognitive analysis
(Moreno et al., 2012). All procedures were approved by the Institutional Animal
Care and Use Committee of the Federal University of Rio de Janeiro (protocol
#IBqM 041).
Intracerebroventricular Injection of Ab Oligomers in Monkeys and
Treatment with Liraglutide
Adult cynomolgus monkeys (Macaca fascicularis) (n = 9) were used (body
weights 4.7–7.0 kg). All procedures were approved by the Queen’s University
Animal Care Committee and were in full compliance with the Canada Council
on Animal Care (Animal Care Protocol Original Munoz-2011-039-Or). Animals
were under the close supervision of an animal technician and the institute
veterinarian. AbOs were infused chronically through an intracerebroventricular
cannula. A total of 4 animals received 100 mg Ab oligomers i.c.v. every 3 days
for 24 days, while 3 animals served as sham-operated controls. Control
animals had the cannula implanted into the lateral ventricle in the samemanner
as the experimental animals but did not receive oligomer injections. Two addi-
tional animals received daily subcutaneous injections of liraglutide (25 nmol/kg)
beginning 1 week prior to Ab oligomer infusion and continuing until the end
of AbO injections. Oligomers were freshly prepared and characterized by
size-exclusion chromatography before each injection. Upon completion of
the experimental protocol, animals were sedated with ketamine (10 mg/kg,
intramuscular) plus buprenorphine (0.01 mg/kg) for analgesia, followed by
intravenous sodium pentobarbital (25 mg/kg). Next, animals were perfused
with PBS and then, sequentially, by 4% paraformaldehyde in PBS, 4% para-
formaldehyde in PBS containing 2.5% glycerol, PBS + 5% glycerol, and
PBS + 10% glycerol. Serial brain sections (40 mm thick) were obtained, and
neuropathological analyses were performed.Inc.
Cell Metabolism
TNF-a, PKR, Insulin Signaling, and MemoryStatistical Analysis
All analyses were performed with GraphPad Prism, and data sets were
assessed for normality parameters prior to significance determination. Values
are expressed as means ± SEM, unless otherwise stated. Statistical confi-
dence levels are indicated in each figure (*p < 0.05; **p < 0.01).
SUPPLEMENTAL INFORMATION
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and six figures and can be found with this article online at http://dx.doi.org/
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